Proteinuria after conversion to sirolimus in kidney transplant recipients: Impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists

Clinical Transplantation

Volumn 24, Issue 5, 2010, Pages 626-630

  Marx, Christian ^a   Busch, Martin ^a   Ott, Undine ^a   Gerth, Jens ^a   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

ACE inhibitors; Angiotensin receptor antagonists; Proteinuria; Renal transplantation; Sirolimus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAPAMYCIN;

ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HYPERTENSION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS;

EID: 78650436368     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01142.x     Document Type: Article

References (18)

1. Fernández-Fresnedo G, Plaza JJ, Sánchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004: 19(suppl 3): iii47.
2. Sancho A, Gavela E, Avila A et al. Risk factors and prognosis for proteinuria in renal transplant recipients. Transplant Proc 2007: 39: 2145.
3. Bumbea V, Kamar N, Ribes D et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005: 20: 2517.
4. Pinheiro HS, Amaro TA, Braga AM, Bastos MG. Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center. Transplant Proc 2006: 38: 3476.
5. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker hospital 8-year experience. Transplant Proc 2003: 35(suppl 3A): 52S.
6. Dittrich E, Schmaldienst S, Soleiman A, Hörl WH, Pohanka E. Rapamycin-associated posttransplant glomerulonephritis and its complete remission after reintroduction of calcineurin inhibitor therapy. Transpl Int 2004: 17: 215.
7. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326.
8. Kuypers DRJ. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005: 28: 153.
9. Roodnat JI, Mulder PG, Rischen-Vos J et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001: 72: 438.
10. Rüster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006: 17: 2985.
11. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006: 17: 889.
12. Opelz G, Zeier M, Laux G, Morath C, Döhler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006: 17: 3257.
13. Schena FP, Pascoe MD, Alberu J et al.; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:164.
14. Vollenbröker B, George B, Wolfgart M, Saleem MA, Pavenstädt H, Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009: 296: F418.
15. Letavernier E, Bruneval P, Vandermeersch S et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009: 24: 630.
16. Resier J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007: 9: 403.
17. Finckenberg P, Inkinen K, Ahonen J et al. Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 2003: 163: 355.
18. Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009: 88: 7.